Menu Search
Equities

CorMedix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CRMD:NMQ

CorMedix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.34
  • Today's Change-0.02 / -0.27%
  • Shares traded1.78m
  • 1 Year change-29.69%
  • Beta1.3052
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CorMedix Inc has grown net income from a loss of -46.34m to a smaller loss of -17.93m primarily through revenue growth (0.00 to 43.47m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the -- growth in revenues contributed enough to still see net income improve.
Gross margin92.61%
Net profit margin75.83%
Operating margin48.51%
Return on assets39.23%
Return on equity75.08%
Return on investment48.05%
More ▼

Cash flow in USDView more

In 2024, cash reserves at CorMedix Inc fell by 3.07m. Cash Flow from Financing totalled 26.32m or 60.54% of revenues. In addition the company used 50.61m for operations while cash from investing totalled 21.23m.
Cash flow per share2.31
Price/Cash flow per share3.47
Book value per share4.78
Tangible book value per share-0.4263
More ▼

Balance sheet in USDView more

CorMedix Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio1.94
Quick ratio1.73
Total debt/total equity0.3893
Total debt/total capital0.2802
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.